Pag-aaral pangklinika para sa Glaucoma sa Texas
8 pag-aaral para sa Glaucoma ang naghahanap ng mga kalahok sa mga site sa Texas.
Opisyal na teksto ng pag-aaral (English)
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Glaukos Clinical Site, El Paso
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07075718iDose TR Administration in an Office-Based Surgery Setting
- Glaukos Investigative Site, Austin
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07816692Clarifying the Optimal Application of SLT Therapy Trial
- Ophthalmology Associates, Fort Worth
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT04967989Rocklatan vs Latanoprost Post-DSLT
- Eye Centers of Southeast Texas, Beaumont
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT07465913Change in IOP Fluctuation After DSLT
- Ophthalmology Associates, Fort Worth
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT07428668Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
- Glaucoma Associates of Texas, Dallas
- University of Texas Southwestern, Dallas
Nagre-recruit
Edad 45 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT07220876Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
- R and R Eye Research, LLC, San Antonio
Nagre-recruitPhase 3
Edad 22 pataas · Lahat ng kasarian · Na-update Okt 20, 2025 · NCT07218796Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
- Houston Eye Associates, Houston
Nagre-recruitPhase 3
Edad 22 pataas · Lahat ng kasarian · Na-update Okt 20, 2025 · NCT07218783Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.